Abstract: Objective: To observe the efficacy and safety of irinotecan (CPT-11)plus capecitabine(xeloda)after first-line chemotherapy failure for patients with advanced colorectal cancer. Methods:Seventy-two patients with advanced colorectal cancer whose disease had progressed after treatment with first-line oxaliplatin and 5-FU/LV chemotherapeutics were treated with irinotecan plus capecitabine:CPT-11 180mg/m 2 d1,dripping into vein in 90 minutes;capecitabine 1250mg/m 2, administered twice dai-ly from day 1 to day 14.The regime was repeated every 21 days for at least 4 consecutive cycles. Theywere assessed on the basis of WHO evaluation standard of objective therapeutic effect for solid tumor.Results: 72 patients were assessable to observe the efficacy and safety. No case was CR(0/72), 16 casewere PR(16/72), response rate was 22.22% (16/72); 44 case were SD(44/72), 12 case were PD(12/72).Median time to progression were 7.6 months (6 to 28 months),median overall survival was 12.8 months.The majority of adverse reaction were nausea,vomiting,anorexia,diarrhea, leucopenia and alopecie.Mostof them were Ⅰ/Ⅱdegree. Conclusions: The combined chemotherapy with irinotecan and capecitabinehas a high therapeutic response with acceptable toxicity in patients with advanced colorectal cancer,and which was convenient to administer with definite efficacy.It could be extensively used.